DiaMedica announces positive outcomes of ReMEDy study for AIS
Category: #health  By Saipriya Iyer  Date: 2020-05-15
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

DiaMedica announces positive outcomes of ReMEDy study for AIS

DiaMedica Therapeutics, a clinical-stage pharmaceutical firm that develops novel therapies for neurological disorders and kidney diseases, has reportedly announced positive top-line outcomes from the company’s Phase II study in AIS (acute ischemic stroke), ReMEDy. DiaMedica also released a business update and financial outcomes for three months ending on March 31, 2020. 

The company hosted a conference call with slides on May 14, 2020, at 7:00 a.m. Central Time. The call would discuss its ReMEDy top-line data, first-quarter financial outcomes and business update during this meeting. 

92 patients suffering from AIS were enrolled to treat them with the company’s candidate, DM199. Multiple plasma-based biomarkers, the Barthel Index, Modified Rankin Scale, and the National Institutes of Health Stroke Scale were the therapeutic efficacy markers for the trial. These markers were evaluated at several points across the study, which also included 90 days post-stroke.

DM199 met primary tolerability and safety endpoints and no serious adverse effects were observed in the trial. As per the top-line phase II outcomes, there was also a demonstrated therapeutic effect in patients who were given tPA (tissue plasminogen activator) before enrollment, but it was not observed in patients receiving mechanical thrombectomy.

The CEO and President of DiaMedica, Rick Pauls stated that the company is thrilled about ReMEDy’s positive top-line outcomes. These results continue to showcase DM199’s excellent safety profile and efficacy signals, consistent with the Kailikang® approval study. Kailikang is KLK1’s urine-derived form that has been used for years as a successful therapy for stroke patients in China. 

Pauls further added that these results strengthen the company’s belief that DM199 has the potential to be an important treatment for stroke victims, enhancing results while providing a substantially longer, up to 24 hours, following the onset of the stroke. The company looks forward to discussing a path to commercialize DM199 with the FDA.

 

Source credit: https://www.businesswire.com/news/home/20200513005761/en/DiaMedica-Announces-Positive-Results-Top-Line-Data-Phase



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...